Newsbenzinga
Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies
· Published
Article summary
Weight Watchers joins LillyDirect for GLP-1 access as Eli Lilly signs a kidney disease research pact with Ascidian worth up to $1.9 billion.
An excerpt from the original article.
Comments —
Loading comments…